ICON Public (NASDAQ:ICLR – Get Rating) had its price objective reduced by analysts at Citigroup from $315.00 to $290.00 in a research note issued to investors on Friday, The Fly reports. The firm presently has a “buy” rating on the medical research company’s stock. Citigroup’s price objective would suggest a potential upside of 33.06% from the stock’s previous close.
Several other research analysts have also weighed in on ICLR. Robert W. Baird reissued a “buy” rating and set a $285.00 price objective on shares of ICON Public in a research note on Friday, May 13th. StockNews.com began coverage on shares of ICON Public in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Guggenheim began coverage on shares of ICON Public in a research note on Monday, May 23rd. They set a “buy” rating and a $285.00 price objective on the stock. Wells Fargo & Company lowered shares of ICON Public from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $280.00 to $250.00 in a research note on Monday, April 25th. Finally, TheStreet downgraded shares of ICON Public from a “b-” rating to a “c” rating in a report on Thursday, March 10th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $281.90.
Shares of NASDAQ ICLR opened at $217.95 on Friday. The firm has a market capitalization of $17.74 billion, a PE ratio of 87.53, a price-to-earnings-growth ratio of 1.15 and a beta of 0.95. The company has a current ratio of 1.13, a quick ratio of 1.13 and a debt-to-equity ratio of 0.63. ICON Public has a 1 year low of $196.34 and a 1 year high of $313.00. The firm’s 50-day moving average is $216.42 and its 200-day moving average is $239.90.
ICON Public (NASDAQ:ICLR – Get Rating) last released its quarterly earnings data on Wednesday, April 27th. The medical research company reported $2.60 earnings per share for the quarter, topping the consensus estimate of $2.48 by $0.12. ICON Public had a net margin of 2.58% and a return on equity of 11.33%. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.88 billion. During the same quarter last year, the firm earned $2.06 EPS. As a group, equities research analysts anticipate that ICON Public will post 10.67 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. TimesSquare Capital Management LLC raised its holdings in shares of ICON Public by 10.4% in the first quarter. TimesSquare Capital Management LLC now owns 249,900 shares of the medical research company’s stock valued at $60,781,000 after purchasing an additional 23,600 shares during the last quarter. Todd Asset Management LLC raised its holdings in shares of ICON Public by 33.1% in the first quarter. Todd Asset Management LLC now owns 69,766 shares of the medical research company’s stock valued at $16,950,000 after purchasing an additional 17,354 shares during the last quarter. FDx Advisors Inc. raised its holdings in shares of ICON Public by 1.7% in the fourth quarter. FDx Advisors Inc. now owns 19,191 shares of the medical research company’s stock valued at $5,943,000 after purchasing an additional 320 shares during the last quarter. SkyView Investment Advisors LLC acquired a new stake in shares of ICON Public in the fourth quarter valued at approximately $409,000. Finally, Dorsey Wright & Associates acquired a new stake in shares of ICON Public in the fourth quarter valued at approximately $4,711,000. Institutional investors own 89.41% of the company’s stock.
ICON Public Company Profile (Get Rating)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Read More
Receive News & Ratings for ICON Public Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ICON Public and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
